Here’s What the Wall Street Thinks About Gossamer Bio (GOSS)

Gossamer Bio, Inc. (NASDAQ:GOSS) is one of the Best Rising Penny Stocks to Buy According to Hedge Funds. On August 5, Gossamer Bio, Inc. (NASDAQ:GOSS) provided second-quarter results and a business update, highlighting the completion of enrollment for its Phase 3 PROSERA Study. The Market has taken the update positively, as the share price has surged more than 8.5% since the announcement.

Recently, on August 19, Patrick Trucchio, analyst from H.C. Wainwright, reiterated a Buy rating on Gossamer Bio, Inc. (NASDAQ:GOSS), with a price target of $10. He noted that the 2025 literature review for Seralutinib has increased confidence in the drug’s lasting effects and also confirmed its relevance to right-heart function. The open-label phase two trial showed sustained improvements among patients, as over seventy-two weeks, there was a drop in pulmonary vascular resistance and better six-minute walk distances.

Management expects results from the Phase 3 PROSERA Study in February 2026; analysts believe this would further prove the drug’s long-term safety and effectiveness.

Gossamer Bio, Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company developing Seralutinib, a drug for treating pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.